NCT03292107

Brief Summary

Study on Management Thrombosis in Greek cancer patients

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
500

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Jun 2016

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

June 1, 2016

Completed
1.3 years until next milestone

First Submitted

Initial submission to the registry

September 20, 2017

Completed
5 days until next milestone

First Posted

Study publicly available on registry

September 25, 2017

Completed
3 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2017

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

February 28, 2018

Completed
Last Updated

April 5, 2019

Status Verified

April 1, 2019

Enrollment Period

1.6 years

First QC Date

September 20, 2017

Last Update Submit

April 4, 2019

Conditions

Thrombosis

Outcome Measures

Primary Outcomes (1)

  • The clinical practice for patients under anticoagulation regime

    Documentation of the clinical practice for patients under anticoagulation regime, for prophylaxis or treatment, in patients with solid tumors, for one year following the protocol initiation date, including high-risk patients as defined in the protocol.

    1 YEAR

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients with solid tumors under anticoagulation regime, for prophylaxis or treatment.

You may qualify if:

  • All patients diagnosed with histologically confirmed solid tumors that are under anticoagulation therapy, during the study timeline.
  • Age ≥ 18 years
  • Signed informed consent

You may not qualify if:

  • Initiation of anticoagulation therapy before the initiation of the study in 2016
  • Age \<18 years
  • No signed informed consent

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Hellenic Society of Medical Oncology

Athens, 11475, Greece

Location

Related Publications (1)

  • Christopoulou A, Ardavanis A, Papandreou C, Koumakis G, Papatsimpas G, Papakotoulas P, Tsoukalas N, Andreadis C, Samelis G, Papakostas P, Aravantinos G, Ziras N, Souggleri M, Kalofonos C, Samantas E, Makrantonakis P, Pentheroudakis G, Athanasiadis A, Stergiou H, Bokas A, Grivas A, Tripodaki ES, Varthalitis I, Timotheadou E, Boukovinas I. Prophylaxis of cancer-associated venous thromboembolism with low-molecular-weight heparin-tinzaparin: Real world evidence. Oncol Lett. 2022 Apr;23(4):115. doi: 10.3892/ol.2022.13235. Epub 2022 Feb 9.

    PMID: 35251346DERIVED

MeSH Terms

Conditions

Thrombosis

Condition Hierarchy (Ancestors)

Embolism and ThrombosisVascular DiseasesCardiovascular Diseases

Study Officials

  • Ioannis Varthalitis, MD

    Hellenic Society of Medical Oncology

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

September 20, 2017

First Posted

September 25, 2017

Study Start

June 1, 2016

Primary Completion

December 31, 2017

Study Completion

February 28, 2018

Last Updated

April 5, 2019

Record last verified: 2019-04

Locations

GR(1)